Azenta announces a strategic investment to accelerate its GENEWIZ gene synthesis business through an exclusive licensing agreement with Elegen and an acquisition of SynPlexity, aiming to advance high-throughput discovery workflows. These moves strengthen the company's biologics portfolio and expand capabilities for synthetic biology and AI-enabled drug discovery.